Get the Daily Brief

All action, no filler. BioBriefs delivers the industry’s 10 must-know updates, every morning.

Latest Biotech News

PerturbAI exits stealth—publishes 8M-cell in vivo CRISPR atlas

March 17, 2026

PerturbAI announced it has emerged from stealth and publicly released an in vivo CRISPR Perturb‑seq atlas mapping gene function across 8 million mouse brain cells. The San Francisco startup...

AlphaFold DB expands—millions of new protein complex predictions added

March 17, 2026

EMBL‑EBI, DeepMind, NVIDIA and Seoul National University jointly released a large-scale set of AI‑predicted protein complex structures to the AlphaFold Database, dramatically expanding resources...

Generative AI drives petascale designed DNA synthesis — Nature Biotechnology

March 17, 2026

Researchers published a Nature Biotechnology paper detailing a generative‑model framework that enables petascale synthesis of designed DNA sequences for engineered biology and cell‑therapy...

Roche strikes Nvidia pact—aims to build pharma’s largest AI compute hub

March 17, 2026

Roche announced a strategic deal with NVIDIA to build an AI 'factory' aimed at accelerating drug and diagnostic development, positioning the Swiss group to compete with peers investing in...

Mayo Clinic engineers milk‑derived nanoparticles for targeted gene therapy

March 17, 2026

Mayo Clinic researchers published preclinical work on milk‑derived nanoparticles engineered to deliver targeted gene therapy to cholangiocarcinoma, an aggressive bile duct cancer. The team showed...

Structure’s oral GLP‑1 posts up to 16% weight loss — Phase 2 readout

March 17, 2026

Structure Therapeutics released 44‑week Phase 2 data showing its oral GLP‑1 candidate aleniglipron produced up to 16% placebo‑adjusted weight loss, positioning the pill as a competitive oral...

BioMarin pauses Voxzogo dosing after hip safety signal

March 17, 2026

BioMarin said it will halt dosing in certain patients across two mid‑stage Voxzogo studies after investigators flagged hip‑related safety events—cases of slipped capital femoral epiphysis...

R1 Therapeutics raises $77.5M to advance kidney disease candidate

March 17, 2026

R1 Therapeutics secured $77.5 million to advance a Phase 2b program targeting hyperphosphatemia in dialysis patients and support clinical development toward a potential market launch by the...

ARPA‑H backs BioCurie—$9.3M to digitize gene therapy manufacturing

March 17, 2026

ARPA‑H awarded BioCurie up to $9.3 million to develop an AI‑powered digital platform designed to accelerate and standardize gene therapy manufacturing across viral and non‑viral modalities....

Trenchant, Invetech partner to commercialize fully automated CGT manufacturing

March 17, 2026

Trenchant BioSystems announced a collaboration with Invetech to advance and commercialize the AutoCell platform, a fully automated cell and gene therapy (CGT) manufacturing system intended for...

Structure’s oral GLP‑1 delivers 16% weight loss – Plans phase 3

March 17, 2026

Structure Therapeutics announced Phase 2 data showing its oral GLP‑1 candidate aleniglipron produced roughly 16% placebo‑adjusted weight loss at 44 weeks. The company reported durable efficacy...

CytomX posts promising ADC data; partner exits a multi‑year T‑cell pact

March 17, 2026

CytomX Therapeutics disclosed expansion‑cohort Phase 1 data for its masked antibody‑drug conjugate Varseta‑M showing objective response rates of roughly 20–32% in heavily pretreated metastatic...

AlphaFold expands into protein complexes: Massive database release

March 17, 2026

EMBL‑EBI, Google DeepMind, NVIDIA and Seoul National University released a large set of AI‑predicted structures for millions of protein complexes into the AlphaFold Database. The collaboration...

Researchers build neurobots with self‑organizing nervous systems

March 17, 2026

Teams led by the Wyss Institute and collaborators reported the first living cellular robots integrated with developing nervous systems—so‑called neurobots—that self‑organize neuronal networks and...

ARPA‑H backs AI platform to scale gene‑therapy manufacturing

March 17, 2026

ARPA‑H awarded BioCurie up to $9.3 million to develop an AI‑driven, data‑centric platform aimed at accelerating and de‑risking gene‑therapy manufacturing. BioCurie will partner with academic and...

Trenchant and Invetech target fully automated point‑of‑care CGT manufacturing

March 17, 2026

Trenchant BioSystems and Invetech confirmed a development partnership to commercialize the AutoCell platform, a fully automated cell‑and‑gene therapy (CGT) manufacturing system designed for...

CirCode cleared to start U.S. trial of circular RNA therapy

March 17, 2026

CirCode Biomed secured FDA clearance to begin a first‑in‑human clinical trial in the U.S. testing a circular RNA therapeutic, marking a significant milestone for an emergent modality. The company,...

Roche inks Nvidia deal to supercharge AI drug and diagnostic factory

March 17, 2026

Roche signed a partnership with Nvidia to bolster the pharma giant’s AI capabilities across drug discovery and diagnostic development, expanding compute infrastructure and software tools used to...

BioVie positions spinout for $19.7M IPO to fund liver‑disease program

March 17, 2026

BioVie announced plans for a roughly $19.7 million IPO for a spinout charged with developing a reformulated low‑blood‑pressure drug as a potential treatment for liver disease. The offering is...

Judge stays RFK Jr. vaccine overhaul – ACIP meetings and schedule frozen

March 17, 2026

A federal judge issued a stay on key elements of Health and Human Services Secretary Robert F. Kennedy Jr.’s effort to overhaul U.S. childhood vaccine policy, blocking the CDC’s revised...